Prevalence of Exposure to Potential CYP450 Pharmacokinetic Drug-Drug Interactions among Patients with Chronic Low Back Pain Taking Opioids

Pain Practice

Volumn 11, Issue 3, 2011, Pages 230-239

  Pergolizzi Jr , Joseph V ^a,b,c   Labhsetwar, Sumedha A ^c   Puenpatom, R Amy ^d   Joo, Seongjung ^d   Ben Joseph, Rami H ^d   Summers, Kent H ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEMA Research   (United States)

^d Endo Pharmaceuticals   (United States)

Author keywords

Chronic low back pain; Drug drug interaction; Opioids; Prevalence of drug interactions

Indexed keywords

AMFEBUTAMONE; AMIODARONE; CARBAMAZEPINE; CELECOXIB; CIMETIDINE; CITALOPRAM; CYTOCHROME P450; DEXAMETHASONE; DIAZEPAM; DIPHENHYDRAMINE; DOXEPIN; DULOXETINE; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; HALOPERIDOL; HYDROXYZINE; KETOCONAZOLE; METHADONE; NEFAZODONE; OPIATE; PAROXETINE; PHENOBARBITAL; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; VENLAFAXINE; VERAPAMIL;

ADULT; ARTICLE; CHRONIC PAIN; DATA BASE; DRUG INTERACTION; DRUG METABOLISM; FEMALE; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANALGESICS, OPIOID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; LOGISTIC MODELS; LOW BACK PAIN; MALE; MIDDLE AGED; PREVALENCE; YOUNG ADULT;

EID: 79955576117     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2010.00413.x     Document Type: Article

References (41)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279:1200-1205.
2. World Health Organization. Safety of Medicines: Adverse Drug Reactions. 2008; Available at: (accessed on August 3, 2009).
3. Kohn LT, Corrigan JM, Donaldson MS, eds. To Err Is Human: Building A Safer Health System. Washington DC: National Academy Press; 2000.
4. Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost of illness model. Arch Intern Med. 1995;155:1949-1956.
5. Bates DW, Cullen DJ, Laird N, etal. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA. 1995;274:29-34.
6. Gandhi TK, Weingart SN, Borus J, etal. Patient safety: adverse drug events in ambulatory care. N Engl J Med. 2003;348:1556-1564.
7. Gurwitz JH, Field TS, Harrold LR, etal. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107-1116.
8. Hartshorn EA, Tatro DS. Principles of drug interactions. In: Tatro DS, ed. Drug Interaction Facts. 5th ed. St. Louis: Facts and Comparisons; 1996:xix.
9. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf. 1993;9:51-59.
10. Dickson M, Bramley TJ, Kozma C, Doshi D, Rupnow MF. Potential drug-drug interactions with antiepileptic drugs in Medicaid recipients. Am J Health Syst Pharm. 2008;65:1720-1726.
11. Saurat JH, Guerin A, Yu AP, etal. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology. 2010;220:128-137.
12. Jankel CA, Speedie SM. Detecting drug interactions: a review of the literature. CICP. 1990;24:982-989.
13. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391-396.
14. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352:2211-2221.
15. Ward MB, Sorich MJ, Evans AM, McKinnon RA. Cytochrome P450 part 3: impact of drug-drug interactions. J Pharm Prac Res. 2009;39:55-58.
16. Bertz RJ, Granneman GR. Use of in vivo and in vitro data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997;32:210-258.
17. Davis MP, Hamsi J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Supp Care Can. 2001;9:442-451.
18. Patterns of medication use in the United States 2005. A report from the Slone Survey. Slone Epidemiology Center at Boston University. 2005. Available at: (accessed on August 9, 2010).
19. Duke Medicine News and Communications. Many drugs prescribed for elderly Americans are risky. 2004. Available at: (accessed on August 1, 2009).
20. Gebhart F. A snapshot of 2003 Rx market. Drug Topics. 2004;148:68.
21. Haider SI, Johnell K, Thorslund M, Fastbom J. Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992-2002. Int J Clin Pharmacol Ther. 2007;45:643-653.
22. Paul E. What Are the Most Common Types of Chronic Pain? 2008. ABC News Health. Available at: (accessed on August 1, 2009).
23. Opana ER. No Known Cyp450 Pharmacokinetic Drug-Drug Interactions at Clinically Relevant Doses. 2009. Available at: (accessed on February 25, 2010).
24. Peng CC, Glassman PA, Marks IR, Fowler C, Castiglione B, Good CB. Retrospective drug utilization review: incidence of clinically relevant drug-drug interactions in a large ambulatory population. J Manag Care Pharm. 2003;9:513-522.
25. Solberg LI, Hurley JS, Roberts MH, etal. Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data. Am J Manag Care. 2004;10:753-759.
26. Schneitman-McIntire OR, Farnen TA, Gordon N, Chan J, Toy WA. Medication misadventures resulting in emergency department visits at an HMO medical center. Am J Health Syst Pharm. 1996;53:1416-1422.
27. Malone DC, Hutchins DS, Haupert H, etal. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm. 2005;62:1983-1991.
28. Wasiak R, Pransky GS, Webster BS. Methodological challenges in studying recurrence of low back pain. J Occup Rehabil. 2003;13:21-31.
29. Wasiak R, Pransky G, Verma S, Webster B. Recurrence of low back pain: definition-sensitivity analysis using administrative data. Spine. 2003;28:2283-2291.
30. MacDonald MJ, Sorock GS, Volinn E, Hashemi L, Clancy EA, Webster B. A descriptive study of recurrent low back pain claims. J Occup Environ Med. 1997;39:35-43.
31. Maetzel A, Li L. The economic burden of low back pain: a review of studies published between 1966 and 2001. Best Pract Res Clin Rheumatol. 2002;16:23-30.
32. Holmquist GL. Opioid metabolism and effects of cytochrome P450. Pain Med. 2009;10:S20-S29.
33. Zhang K, Young C, Berg J. Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions. J Manag Care Pharm. 2006;12:686-687.
34. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245-1251.
35. Sandson N. Drug-drug interactions: the silent epidemic. Psychol Serv. 2005;56:22-24.
36. Tobi H, Faber A, van den Berg PB, Drane JW, de Jong-van den Berg LTW. Studying co-medication patterns: the impact of definitions. Pharmacoepidemiol Drug Saf. 2007;16:405-411.
37. Bushradt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3:383-389.
38. Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract. 2005;17:123-132.
39. Bregnhoj L, Thirstrup S, Kristensen MB, Bjerrum L, Sonne J. Prevalence of inappropriate prescribing in primary care. Pharm World Sci. 2007;29:109-115.
40. Werder SF, Preskorn SH. Managing Polypharmacy: Walking the Fine Line Between Help and Harm. [Electronic version] Current Psychiatry Online. 2003;2(2). Available at: (accessed on March 23, 2010).
41. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics. 2003;44:167-171.